Bristol Myers Squibb spells out OS benefit of Opdivo/Yervoy combo plus 'limited' chemotherapy — is it enough to change practice?
Normally when a PD-1 inhibitor is given with chemotherapy as a first-line treatment of non-small cell lung cancer — a regimen popularized by Merck and its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
